Combination treatment for advanced lung cancer without driver mutations
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of an immunotherapy drug (QL1706) with chemotherapy and a special radiation technique (Quad Shot) for people with advanced non-small cell lung cancer that has spread. The goal is to see if this combination can help control the cancer better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of lung cancer called squamous cell carcinoma or adenocarcinoma.
- Your cancer has spread to other parts of the body (stage IV) and you have at least two tumors that can be measured.
- Your cancer does not have certain genetic changes (driver mutations) that can be targeted with specific drugs.
- You are generally able to take care of yourself (ECOG performance status 0 or 1).
- Your blood counts, liver, kidney, and heart function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests giving radiation and immunotherapy together to people with advanced lung cancer that hasn't been treated yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.